Skip to main content
Signal8

Disc Medicine Announces Multiple Presentations Across Portfolio at the 68th American Society of Hematology (ASH) Annual Meeting

$IRONPress releaseNov 4, 2026, 9:05 AM ET

Disc Medicine will present data across its entire portfolio at the ASH Annual Meeting in New Orleans, December 12-15, 2026, including three oral presentations. Orals feature RALLY-MF Phase 2 data for selcodebart (DISC-0974) in myelofibrosis anemia and RESTORE-PV Phase 2 data for DISC-3405 in polycythemia vera, plus initial Phase 1b DISC-3405 data in sickle cell disease in poster form. Bitopertin, the lead asset, gets a Phase 3 APOLLO baseline-characteristics poster and preclinical orals, following what management calls highly successful APOLLO topline results.

Key figures

Drug Name
bitopertin
Phase Of Trial
Phase 3
Conference
ASH Annual Meeting, December 12-15, 2026, New Orleans
Oral presentations
3
Programs presenting
3

AI analysis

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.